Actelion (SWX: ATLN) went public in April 2000 and is developing therapies for severe cardiovascular diseases, including pulmonary arterial hypertension.
J&J gets a $30B Actelion buyout and a new partner as Clozel’s team spins out with the pipeline
Actelion is going public – Placement of up to 1 million shares – SWX New Market Listing
J&J gets a $30B Actelion buyout and a new partner as Clozel’s team spins out with the pipeline
Actelion is going public – Placement of up to 1 million shares – SWX New Market Listing
Location: Switzerland, Basel-City, Basel
Investors 1
| Date | Name | Website |
| - | Atlas Vent... | atlasventu... |
Mentions in press and media 5
| Date | Title | Description |
| 29.11.2016 | Term Sheet — Tuesday, November 29 | Today in Fallen Unicorns Two shareholders have filed a class action lawsuit against Theranos, accusing the company of fraud and negligence. I believe it’s not terribly common to see private companies involved in class action shareholder law... |
| 05.08.2014 | New pharma partner for PatientsLikeMe will gather insights from non-Hodgkins lymphoma patients | About 18 months ago, PatientsLikeMe developed its OpenResearchExchange to connect researchers designing clinical trials with patients to get their feedback on health measures. Its latest pharmaceutical partner Actelion Pharmaceuticals wants... |
| 20.06.2014 | What’s in pharma’s future? Patient centricity, healthcare services, competition with big data firms | Christoph Schmidt, the head of global commercial excellence at Actelion Pharmaceuticals, agrees. “Patient centricity as a strategy is also the result of the shift in decision-making power in the more complex and educated stakeholder landsca... |
| - | New pharma partner for PatientsLikeMe will gather insights from non-Hodgkins lymphoma patients | About 18 months ago, PatientsLikeMe developed its OpenResearchExchange to connect researchers designing clinical trials with patients to get their feedback on health measures. Its latest pharmaceutical partner Actelion Pharmaceuticals wants... |
| - | What’s in pharma’s future? Patient centricity, healthcare services, competition with big data firms | Healthcare reform is prompting consolidation and leaner pharmaceutical companies and personalized medicine applications are a source of growing interest. But what other trends figure in to the future of the life sciences industry? How about... |